Cannabidiol: brief compilation over a versatile molecule




Cannabidiol; Therapeutic use; Cannabis; Central Nervous System.


Cannabis sativa has been applied for medicinal purposes for thousands of years. Cannabidiol is the main non-psychotropic compound in Cannabis sativa, and has its therapeutic effect extremely linked to the central nervous system, presenting pharmacological properties with great potential for the treatment of several pathologies. The aim is to identify and relate the therapeutic effects of cannabidiol in medicine, focusing on its therapeutic potential in epilepsy, autism, Parkinson's disease, Alzheimer's disease, oncological diseases, and chronic pain. In addition to presenting a brief history of cannabidiol and its chemical and pharmacological properties acting on the Central Nervous System. Integrative literature review, where articles were reviewed in Portuguese and English, based on PubMed, Scielo and Public Agencies. In 1960, the chemical structures of the main components of cannabis were identified, characterizing cannabidiol as a cannabinoid, which binds to cannabinoid receptors throughout the human body, known as CB1 and CB2. The endocannabinoid system, described in 1990, further demonstrated the therapeutic properties of cannabidiol, elucidating its neuroprotective, antiepileptic, anxiolytic, antipsychotic, anti- inflammatory, anti-tumor, antioxidant, and anticonvulsant properties. Cannabinoids may, in the future, be an important therapeutic option in the treatment of Parkinson's and Alzheimer's diseases, epilepsy, autism, neoplasms and still acting in the relief of pain. This is due to the absence of psychoactive effects and cognition, safety, good tolerability, clinical trials with positive results and the wide spectrum of pharmacological actions.

Author Biography

Flávia de Sousa Gehrke, Instituto de Assistência Médica ao Servidor Público Estadual; Centro Universitário FMABC

Centro Universitário FMABC (FMABC), Brazil

Instituto de Assistência Médica ao Servidor Público Estadual (IAMPSE), Brazil


Abrams, D. I. (2018). The therapeutic effects of Cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering and Medicine report. European Journal of Internal Medicine, 49, 7–11.

Ascenção, M. D., Lustosa, V. R. & da Silva, L (2016). J. Cannabinoids in the treatment of chronic pain. Rev Med Saude Brasilia, 5 (3), 255-63

Bonfá, L., Vinagre, R. C. O. & Figueiredo, N. V. (2008). Cannabinoid use in chronic pain and palliative care. Rev. Bras. Anestesiol, 58(3).

Casey, S. & Vaughan, C. W. (2018). Plant-Based Cannabinoids for the Treatment of Chronic Neuropathic Pain. Medicines, 5(3), 67.

Couch, D.G.; Tasker, C.; Theophilidou, E. et al (2017). Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon. Clin Sci, 131(21), 2611-2626.

Crippa, J. A. S.; Zuardi, A. W.; Hallak, J. E. C. (2010). Therapeutic use of cannabinoids in psychiatry. Rev. Bras. Psychiatrist, 32(1). 44462010000500009

de Faria, S. M.; Fabricio, D. M.; Tumas, V. et al (2020). Effects of acute administration of Cannabidiol on anxiety and tremors induced by the public speaking simulation test in patients with Parkinson's disease. J Psychopharmacol, 34(2), 189-196. http://doi: 10.1177/0269881119895536

dos Santos, R.G.; Hallak, J.E.C.; Crippa1, J.A.S. (2018). The use of cannabidiol (CBD) in the treatment of Parkinson's disease and its comorbidities. Rev Med, 98(1), 46-51.

Giacoppo, S.; Mandolino, G.; Galuppo, M. et. al. (2014). Cannabinoids: New promising agents in the treatment of neurological diseases. Molecules, 19(11), 18781-18816,

Gontijo, E.C.; Castro, G. L; Petito, A. D. C. et. al (2016). Cannabidiol and its therapeutic applications. Refacer, 5(1).

Johnson, J.R.; Burnell-Nugent, M.; Lossignol, D. et. al. (2010). Multicenter, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC: CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain. Journal of Pain and Symptom Management, 39 (2), 167–179.

Lopes, R.M. (2014).Canabinoides help to uncover common etiological aspects and bring hope for the treatment of autism and epilepsy. Revista da Biologia, 13(1), 43-59.

Matos, R.L.A.; Spinola, L. A.; Barboza, L. L. et al (2017). The Use of Cannabidiol in the Treatment of Epilepsy. Rev. Virtual Quim., 9 (2), 786-814. 6835.20170049

Massi, P.; Solinas, M.; Cinquina, V. et. al. (2013). Cannabidiol as potential anticancer drug. British Journal of Clinical Pharmacology, 75(2), 303–312. 2125.2012.04298.x.

Oliveira, A.D.C. & Pottker, C. A. (2019). Considerations about Canabidiol in the psychotherapeutic process of children with autistic spectrum disorder. Rev. UNINGÁ Review, 34(4), 24-37.

Pereira, F.A.; Torres, A. C.; Philadelpho, V. O. et. al (2018). Effects of Canabidiol on the frequency of epileptic crisis: a systematic review. Brazilian Journal of Neurology and Psychiatry, 22(1), 86-100

Santos, A.B.; Scherf, J.; Mendes, R. C. (2019). Efficacy of cannabidiol in the treatment of seizures and diseases of the central nervous system: systematic review. Acta Brasiliensis, 3(1), 30-34.

Silva, D. O. F.; Reis, M. C.; Santos, B. E. M. et al (2017). The Use of Cannabidiol in the Treatment of Anxiety. Rev Med Saude Brasilia; 6(2), 255-60.

Silva, R.C et. Al (2019). Use of Canabidiol in the treatment and prevention of Alzheimer's evil: scientific and technological prospection. ISTI/SIMTEC, 10(1), 912-921.

Szabady, R.L.; Louissaint, C.; Lubben, A. et al (2018). Intestinal P-glycoprotein exports endocannabinoids to prevent inflammation and maintain homeostasis. J Clin Invest, 128(9):4044-4056.




How to Cite

PAULA, C. B. C. O. de .; BALDACCI, E. A. .; CHENG, L. C. .; GOZZI, M. B. .; SHIBUYA, P. T. .; NICOLAU, L. A. D. .; MEDEIROS, J. V. R. .; ANGHINAH, R.; OLIVEIRA, J. V. de .; GEHRKE, F. de S. .; MENEZES-RODRIGUES, F. S. Cannabidiol: brief compilation over a versatile molecule. Research, Society and Development, [S. l.], v. 10, n. 14, p. e452101422239, 2021. DOI: 10.33448/rsd-v10i14.22239. Disponível em: Acesso em: 17 jun. 2024.



Review Article